TIDMYGEN
Yourgene Health PLC
11 March 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Yourgene Genomic Services portfolio expansion
Cytox's genoSCORE(TM) -LAB test can predict the risk of
developing Alzheimer's disease
Yourgene Genomic Services to run the array-based test at
Citylabs 1.0 in Manchester
Manchester, UK - 11 March 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that Yourgene
Genomic Services ("YGS") has signed a contract with Cytox Ltd
("Cytox"), a collaborative partner, to run Cytox's genetic test,
genoSCORE(TM) -LAB*, which can predict the risk of an individual's
cognitive decline due to Alzheimer's disease, in the Company's
Citylabs 1.0 in Manchester.
Under the collaboration agreement, announced on 21 October 2020
and the successful conclusion of the beta testing study, YGS will
run the array-based test with patient samples coming from the UK
and Europe. Both blood and saliva samples will be sent to YGS to be
analysed against an array of c.100,000 common genetic variations or
biomarkers that are associated with, or protective against, the
risk of developing Alzheimer's disease. The test will be able to
detect the necessary genotypes to calculate individual polygenic
risk scoring ("PRS") and generate an overall risk of cognitive
decline due to the disease. A risk report will be produced,
providing recommendations for positive steps for the patient to
take to delay the onset of Alzheimer's disease.
With modifiable factors accounting for more than 30% of the risk
for Alzheimer's, the adoption of behaviours to monitor and treat
factors such as hypertension, elevated cholesterol and smoking, is
likely to bring benefit to the time of onset and rate of cognitive
decline in Alzheimer's disease. In Europe alone, there are an
estimated 1.6 million new cases of dementia each year, of which
800,000 are Alzheimer's disease.
Commenting, Lyn Rees, CEO of Yourgene, said : "We are pleased to
update shareholders on this exciting development with our partner
Cytox, highlighting the strengths and scope of our YGS
capabilities. This is an additional test in our growing portfolio
around precision health and provides another endorsement of the CRO
core services offering YGS provides to our partners."
* geno SCORE-LAB only requires a blood or saliva sample. An
easy-to-use mouth swab enables elderly and vulnerable patients to
provide a sample from home if they are self-isolating due to
COVID-19, or not wishing or easily able to attend a healthcare
setting. As such, genoSCORE-LAB offers an easy to access
alternative to existing invasive lumbar puncture tests, and
expensive scanning procedures.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
About Cytox ( www.cytoxgroup.com )
Without new drug therapies, the economic and healthcare cost
burden of dementia - including Alzheimer's disease (AD) - will
continue to rise, and now exceeds $1tn per year6. AD - a highly
complex disease with risk factors based in genetics, lifestyle,
age, and environment - has seen no new approved drug therapy since
2003; and clinical trial failure rates run at 99%7. Cytox's
products genoSCORE-LAB and genoTOR use Polygenic Risk Scoring (PRS)
to predict the risk of individuals developing AD, and to improve
clinical trial outcomes through patient stratification and the
genetic characterisation of the disease. Cytox's genoSCORE-LAB test
has the potential to transform the diagnosis and prognosis of
Alzheimer's disease, unlocking a number of new approaches to
treating and managing this critical disease. Cytox has ISO 13485
accreditation, for the provision of medical devices to meet
customer and regulatory requirements.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFFEIVTIILIL
(END) Dow Jones Newswires
March 11, 2021 02:00 ET (07:00 GMT)
Premaitha (LSE:NIPT)
過去 株価チャート
から 5 2024 まで 6 2024
Premaitha (LSE:NIPT)
過去 株価チャート
から 6 2023 まで 6 2024
